In order to determine the impact of RvD2 alone or in combination with WRW4 (a specific blocker peptide of the ALX/FPR2 receptor) on airway hyperresponsiveness triggered by TNF-α, various pre-treatments were assessed on the pharmaco-mechanical responses in human bronchial explants. The gene discussed is TNF; the disease is airway hyperresponsiveness.